Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1506765 | 0.96 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL11313405 | 0.96 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| Iodide SCHEMBL17865375 | 0.96 | ALDH1A1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL8474049 | 0.85 | CYP1A2 (0.36) | ALDH1A1LMNA | |
| Acetic Acid SCHEMBL5532865 | 0.84 | FFAR3 (0.41) | LMNA | |
| Formic Acid SCHEMBL4634652 | 0.84 | — | — | |
| Sulfuric Acid SCHEMBL4634973 | 0.84 | CA5A (0.35) | — | |
| SCHEMBL2156409 | 0.82 | TRPV1 (0.33) | ALDH1A1LMNA | |
| Nitric Acid SCHEMBL4635145 | 0.80 | CA5A (0.42) | — | |
| SCHEMBL14481580 | 0.80 | TSHR (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271719-B1 | AQUEOUS COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-11-27 | — | — | EP | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | claimed |
| US-20240063376-A1 | BULK SI-ANODE FOR USE IN PROTON-CONDUCTING RECHARGEABLE BATTERIES | KAWASAKI MOTORS, LTD. (JP) | 2024-02-22 | — | — | US | claimed |
| US-11905491-B2 | Post CMP cleaning compositions | ENTEGRIS, INC. (US) | 2024-02-20 | — | — | US | claimed |
| US-20240018369-A1 | AQUEOUS COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC | 2024-01-18 | — | — | US | claimed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3037889-B1 | MEMBER FOR ELECTROPHOTOGRAPHY AND METHOD OF PRODUCING THE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KK (JP) | 2023-11-29 | — | — | EP | claimed |
| EP-4225882-A1 | POST CMP CLEANING COMPOSITIONS | Entegris, Inc. (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2023007751-A1 | SI-CONTAINING METAL HYDRIDES WITH EXPANDED SUPERLATTICE STRUCTURE FOR USE IN PROTON-CONDUCTING RECHARGEABLE ELECTROCHEMICAL CELLS | KAWASAKI MOTORS, LTD. (JP) | 2023-02-02 | — | — | WO | claimed |
| WO-2022145026-A1 | SI-CONTAINING ALLOY FOR THE ANODE OF PROTON-CONDUCTING RECHARGEABLE BATTERIES | KAWASAKI MOTORS, LTD. (JP) | 2022-07-07 | — | — | WO | claimed |
| WO-2005107712-A1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | HERMES BIOSCIENCES, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005009601-A2 | LOW-ODOR CATALYST FOR ISOCYANATE-DERIVED FOAMS AND ELASTOMERS | HUNTSMAN PETROCHEMICAL CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20020007036-A1 | High-functionality polyisocyanates | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-17 | — | — | US | claimed |
| EP-0763132-B1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB INC (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1998057910-A2 | CYCLOOXYGENASE-I SELECTIVE INHIBITORS AND THE USE THEREOF AS ANALGESIC, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1998-12-23 | — | — | WO | claimed |
| US-5719035-A | MEASURING FLUORESCENT ENZYME PRODUCT | ISOLAB, INC. (US) | 1998-02-17 | — | — | US | claimed |
| EP-0763132-A4 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB INC (US) | 1997-06-18 | — | — | EP | claimed |
| EP-0763132-A1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| US-5538857-A | FLUORESCENCE | ISOLAB, INC. (US) | 1996-07-23 | — | — | US | claimed |
| WO-1995033072-A1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB, INC. (US) | 1995-12-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007036-A1 | High-functionality polyisocyanates | PCBP1, C9, CYP1B1 | ALDH1A1 256/4885LMNA 1786/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | ALDH1A1 3441/4885LMNA 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.